A Study of the Long-Term Safety of Tafamidis in Subjects with Transthyretin Cardiomyopathy

Overview

About this study

The purpose of this study is to evaluate the safety of oral daily dosing of tafamidis meglumine for patients who have either transthyretin genetic variations or wild-type transthyretin, resulting in amyloid disease of the heart muscle.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Completion of 30 months of study treatment on Pfizer Protocol B3461028

Exclusion Criteria

  • Liver and/or heart transplant, or an implanted cardiac mechanical assist device

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

D Steidley, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20257592

Mayo Clinic Footer